1. First International Psoriatic Arthritis Working Group Meeting: 8/15-17/03 NYC Philip Mease MD

2. Acknowledgements Major Sponsors –Abbott –Amgen –Biogen –Centocor –Genentech –Novartis –Schering-Plough –Serono –Wyeth Minor Sponsors –Aventis

3. Personnel Project Manager – Robin Shapiro (Health Advocacy Strategies) Conference Management –New World Health Erin Ben-Hayon Victoria Marano Lisa Davenport

4. Conference Steering Committee Steering Committee –Christian Antoni –Dafna Gladman –Desiree van der Heijde –Philip Helliwell –Joachim (Jochen) Kalden –Artie Kavanaugh –Gerald (Jerry) Krueger –Philip Mease –Alan Menter –Peter Nash –Christopher (Chris) Ritchlin –Josef Smolen –William (Will) Taylor

5. History Model: ASAS working group est. 1995 Core rheumatology group: CASPAR est. 2000 Idea conception: NY AS meeting 8/02 Idea discussion: Gent SpA meeting 10/02 PsA working group authorized: CASPAR meeting, ACR 10/02 Initial rheumatology group meeting: Lisbon, EULAR 6/03 Inaugural combined rheum-derm meeting planning: 4/03 – current Major stimuli –Industry-sponsored PsA/PSO therapy trials with concomitant networking of rheum/derm experts, patient leagues, and regulatory agencies over past five years –Research efforts in basic science, clinical issues, outcome assessment –Awareness promoted by new developments and patient leagues

6. Needs Improve awareness of and communication between experts in PsA and PSO, especially between rheumatologists and dermatologists Identify and promote key domains of inquiry in PsA and PSO Develop updated classification criteria of PsA (CASPAR) Validate and standardize outcome assessment tools in PsA and PSO, both for basic clinical and therapeutic studies Improve awareness of and communication between PsA/PSO experts and other interested entities, including patient leagues, industry, other physicians, and the public Improve educational efforts about PsA and PSO Improve standardization of clinical registries Development of treatment guidelines

7. Goals of Psoriatic Arthritis Working Group To establish an active network of experts in psoriatic arthritis (PsA) and psoriasis (PSO) in order to further basic research, clinical care, and education To establish an active partnership between PsA/PSO experts and representatives of patient service leagues, the biopharmaceutical industry, regulatory agencies, and other concerned groups

8. Objectives of Inaugural Meeting Facilitate acquaintance of rheumatology and dermatology PsA/PSO experts, methodologists, representatives of patient service leagues, the biopharmaceutical industry, and regulatory agencies Share top line, current knowledge about PsA/PSO basic science, clinical, and treatment issues Discuss domains of inquiry in PsA/PSO and achieve consensus re. key domains for outcomes research in PsA/PSO

9. Meeting Objectives (cont.) Establish organizational framework of PsA Working group –Non-profit organization –Funding –Decision making –Leadership –Committees (“subgroups”, “cells”) –Nature of relationship with patient leagues, industry, other entities (regulatory agencies, professional societies, etc.) –Process of “on-line” work/productivity –Publications –Meetings –Discuss potential name of organization

10. Meeting Objectives (cont.) Review, discuss, and determine pathway to consensus on instruments of assessment in PsA/PSO Understand history, activities, and process of AS working group as a template for PsA working group Review clinical registry efforts in PsA and PSO and discuss possible standardization of registries Understand differences and similarities in the “landscape of care” of PsA and psoriasis in the US, Canada, Europe, and Australia/New Zealand

11. Meeting Objectives (cont.) Discuss collaboration with patient leagues and industry regarding physician and patient education efforts Conduct group discussion and consensus-decision-making regarding domains of inquiry Establish focused committees for ongoing work/productivity so that momentum is not lost between meetings Select support group and technology (software) for on-line activities Establish specific milestones to prepare for OMERACT PsA module, 5/04 Establish agenda for next meeting, Friday, October 24, 12- 6 PM, Orlando Convention Center (ACR) STAY ON TIME! ENJOY EACH OTHER!

12. Examples of Potential Committees Clinical Registries Education/Publications/Liaison with Patient Leagues OMERACT Planning Tools of Assessment –Rheum –Derm Steering Committee/Meeting Planning/On Line Productivity/Governance/Finance/Membership CASPAR

13. Some Elements of Mission Statement Increasing awareness and early diagnosis of the disease Development and validation of assessment tools The evaluation of treatment modalities in order to promote clinical research with the ultimate goal to improve outcome of the disease Promote basic research about disease pathophysiology Foster interdisciplinary communication